MDP — Medexus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$87.10m
- CA$130.70m
- $113.05m
- 75
- 95
- 72
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.9 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 3.07 | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | 5.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.84% | ||
| Return on Equity | 11.37% | ||
| Operating Margin | 9.33% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 55.51 | 79.66 | 76.7 | 108.1 | 113.05 | 109.22 | 102.04 | 34.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -44.44 | +13.48 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 2021
- Public Since
- March 3rd, 2012
- No. of Employees
- 98
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 32,258,353
- Address
- 10 King Street East, Suite 600, TORONTO, M5C 1C3
- Web
- https://www.medexus.com/en_US
- Phone
- +1 5147622626
- Contact
- Tina Byers
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for MDP
Q4 2025 Medexus Pharmaceuticals Inc Earnings Release
Q1 2026 Medexus Pharmaceuticals Inc Earnings Release
Medexus Pharmaceuticals Inc Annual Shareholders Meeting
Similar to MDP
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
What is the Medexus Pharmaceuticals share price?
As of Today at 21:58 UTC, shares in Medexus Pharmaceuticals are trading at CA$2.70. This share price information is delayed by 15 minutes.
How has the Medexus Pharmaceuticals share price performed this year?
Shares in Medexus Pharmaceuticals last closed at CA$2.70 and the price had moved by +45.16% over the past 365 days. In terms of relative price strength the Medexus Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +29.06% over the past year.
What are the analyst and broker recommendations for Medexus Pharmaceuticals?
The overall consensus recommendation for Medexus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medexus Pharmaceuticals dividend yield?
Medexus Pharmaceuticals does not currently pay a dividend.
Does Medexus Pharmaceuticals pay a dividend?
Medexus Pharmaceuticals does not currently pay a dividend.
When does Medexus Pharmaceuticals next pay dividends?
Medexus Pharmaceuticals does not currently pay a dividend.
How do I buy Medexus Pharmaceuticals shares?
To buy shares in Medexus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medexus Pharmaceuticals?
As of the previous close price of CA$2.70, shares in Medexus Pharmaceuticals had a market capitalisation of CA$87.10m.
Where are Medexus Pharmaceuticals shares listed?
Here are the trading details for Medexus Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: MDP
What kind of share is Medexus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Medexus Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medexus Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Medexus Pharmaceuticals is CA$6.11. That is 126.2% above the last closing price of CA$2.70.
Analysts covering Medexus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.05 for the next financial year.
Find out moreWhat is the trend in the Medexus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medexus Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +4.85%.
As of the last closing price of CA$2.70, shares in Medexus Pharmaceuticals were trading -1.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medexus Pharmaceuticals PE Ratio?
The Medexus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$2.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medexus Pharmaceuticals?
We do not have data on Medexus Pharmaceuticals' directors